CytomX Spends $25.2 Million As Revenue Shrinks To $1.7 Million — Cancer Trials Advance
The drug developer expects funding to last into the second half of 2028, with a colorectal-cancer trial update due in January 2027.
CytomX Therapeutics, which develops cancer drugs designed to activate mainly inside tumors, reported third-quarter revenue of $1.7 million against operating expenses of $25.2 million Thursday, according to results accompanying its SEC filing. Revenue fell from $6.0 million a year earlier, primarily because the company finished its work under an Astellas collaboration in the second quarter.
Higher Costs, A Wider Loss
Operating expenses rose $3.5 million from $21.7 million a year earlier. Research and development accounted for $16.5 million, up $1.2 million from $15.3 million; higher personnel expenses were partly offset by lower spending on Varseta-M because of manufacturing timing.
Administrative expenses increased $2.3 million to $8.7 million from $6.4 million. Personnel and consulting expenses contributed to the increase, along with rent during the move to CytomX’s new Emeryville headquarters.
The quarterly net loss widened to $19.998 million from $14.229 million. Loss per share stayed at $0.09, with the weighted-average share count used in that calculation rising to 219,106,651 from 165,004,291.
For the first nine months, revenue totaled $13.365 million versus $75.538 million a year earlier. Operating expenses reached $80.320 million from $69.970 million, and a $9.142 million net profit became a $58.912 million net loss.
CytomX nevertheless ended the third quarter with $348.0 million in cash, cash equivalents and investments. Management expects those funds to support operations into the second half of 2028.
Varseta-M Moves Toward An Approval Study
CytomX’s PROBODY platform masks biologic medicines to limit their activity in healthy tissue and concentrate it inside tumors. Its clinical programs remain in early-stage testing, led by varsetatug masetecan, or Varseta-M, an antibody carrying a cancer-killing drug and initially being developed for metastatic colorectal cancer.
Varseta-M received FDA Fast Track designation in August for metastatic colorectal cancer that has returned or resisted treatment. CytomX expects a January 2027 update on testing the drug alone, including dose selection and a possible strategy for a study intended to support approval. That study could begin in the first half of 2027.
Sean McCarthy, CytomX’s chairman and CEO, said the development strategy is “intended to urgently advance Varseta-M for the maximum benefit of cancer patients.”
An ongoing trial pairs Varseta-M with bevacizumab in patients who have received later lines of colorectal-cancer treatment. After selecting a dose and schedule, CytomX plans to focus on patients receiving second- and third-line treatment; initial data are anticipated in the first half of 2027.
By the end of 2026, the company plans to start an early- to mid-stage trial combining Varseta-M with bevacizumab, 5-fluorouracil and leucovorin as second-line treatment. Enrollment has also begun in groups testing Varseta-M alone for gastric and gastroesophageal junction cancers, plus pancreatic ductal adenocarcinoma and biliary tract cancer selected for the EpCAM tumor target.
CX-801 Reaches Higher Dose Levels
CytomX’s other clinical candidate, CX-801, is a masked interferon alpha-2b being tested in advanced melanoma. Testing the drug alone has reached the fourth dose level, and the company said it has generally been well tolerated at doses exceeding the approved dose of unmasked interferon alpha-2b.
The trial combining CX-801 with KEYTRUDA, or pembrolizumab, continues enrolling patients and has cleared the third dose level. CytomX expects initial combination data in the first half of 2027.
The January 2027 Varseta-M update is expected to address both the dose CytomX selects and its potential path toward an approval-focused colorectal-cancer study.
Sources
- 8-K Filing — CytomX Therapeutics, Inc. (CTMX) — SEC EDGAR
- Exhibit ctmx-ex99_1.htm — CytomX Therapeutics, Inc. 8-K exhibit — SEC EDGAR
- CytomX Therapeutics Q3 2026 Earnings Call Transcript — benzinga.com
- CytomX Therapeutics Announces Q3 2026 Financial Results and — globenewswire.com